Kleinstiver BP, Prew MS, Tsai SQ, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523(7561):481-5. doi:10.1038/nature14592
Lobritz MA, Belenky P, Porter CBM, et al. Antibiotic efficacy is linked to bacterial cellular respiration. Proc Natl Acad Sci U S A. 2015;112(27):8173-80. doi:10.1073/pnas.1509743112
Simon-Loriere E, Faye O, Faye O, et al. Distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic. Nature. 2015;524(7563):102-4. doi:10.1038/nature14612
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372(26):2481-98. doi:10.1056/NEJMoa1402121
Kwiatkowski DJ, Wagle N. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses? EBioMedicine. 2015;2(1):2-4. doi:10.1016/j.ebiom.2014.12.011
McNeish J, Gardner JP, Wainger BJ, Woolf CJ, Eggan K. From Dish to Bedside: Lessons Learned While Translating Findings from a Stem Cell Model of Disease to a Clinical Trial. Cell Stem Cell. 2015;17(1):8-10. doi:10.1016/j.stem.2015.06.013
Kang HB, Fan J, Lin R, et al. Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell. 2015;59(3):345-58. doi:10.1016/j.molcel.2015.05.037
Crago AM, Chmielecki J, Rosenberg M, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54(10):606-15. doi:10.1002/gcc.22272
Wu SC, Li LS, Kopp N, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015;28(1):29-41. doi:10.1016/j.ccell.2015.06.005
Van Allen EM, W Y Lui V, Egloff AM, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015;1(2):238-44. doi:10.1001/jamaoncol.2015.34